Cholestatic hepatic fibrosis
Conditions
Interventions
Experimental group:Lidanheji
Control Group:Routine liver protection treatment
Sponsors
Wuhan Children's Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: (1) Infants with cholestatic liver disease, aged less than 3 months. (2) Patients who have undergone two weeks of conventional treatment with Chinese medicine, combination of Chinese and Western medicine (observation group), or Western medicine (control group) without significant improvement, or whose jaundice symptoms have improved but the observed indicators have not decreased or improved by 30%. (3) Patients diagnosed with biliary atresia after abdominal exploration.
Exclusion criteria
Exclusion criteria: Genetic metabolic liver diseases, viscous bile syndrome, choledochal cyst, tumor compression, endocrine diseases, drug-toxic causes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Bilirubin;Direct Bilirubin;Alanine Aminotransferase;Glutamic-oxaloacetic transaminase;Gamma-glutamyl transferase;Hyaluronic acid;Laminin;Procollagen type III;Type IV collagen; | — |
Secondary
| Measure | Time frame |
|---|---|
| Alkaline phosphatase;Total bile acids; | — |
Countries
China
Contacts
Public Contactyiwei
Wuhan Children's Hospital
Outcome results
None listed